PTPA and plasma cell myeloma: While compounds such as bortezomib (FDA-approved for multiple myeloma) and Fingolimod (FDA-approved for multiple sclerosis) have shown potential to modulate PP2A or CIP2A activity in preclinical studies, their use specifically for targeting CIP2A in cancer remains experimental.